Discover the breakthrough role of GLP-1 receptor agonists in cardiovascular health, FDA-approved for patients managing diabetes and obesity.

The federal government lowers obesity drug prices and expands Medicare coverage, impacting millions of patients and primary care providers with new access and cost structure.

Trump administration proposes a Medicare and Medicaid pilot to cover GLP-1 weight loss drugs, highlighting access benefits alongside fraud and regulatory oversight challenges.

Novo Nordisk expands access to Wegovy with a new self-pay pricing program and pursues legal actions against unauthorized compounded drug sales, impacting the obesity treatment market.